BACKGROUND: Lynch syndrome is an autosomal dominantly inherited disorder caused by germline mutations in DNA mismatch repair (MMR) genes. Previous studies have shown that MMR gene mutation carriers are at increased risk of colorectal, endometrial, and several other cancers following an initial diagnosis of colorectal cancer. We estimated cancer risks following an endometrial cancer diagnosis for women carrying MMR gene mutations. METHODS: We obtained data from the Colon Cancer Family Registry for a cohort of 127 women who had a diagnosis of endometrial cancer and who carried a mutation in one of four MMR genes (30 carried a mutation in MLH1, 72 in MSH2, 22 in MSH6, and 3 in PMS2). We used the Kaplan-Meier method to estimate 10- and 20-year cumulative risks for each cancer. We estimated the age-, country-, and calendar period-specific standardized incidence ratios (SIRs) for each cancer, compared with the general population. RESULTS: Following endometrial cancer, women carrying MMR gene mutations had the following 20-year risks of other cancer cancers: colorectal cancer (48%, 95% confidence interval [CI] = 35% to 62%); cancer of the kidney, renal pelvis, or ureter (11%, 95% CI = 3% to 20%); urinary bladder cancer (9%, 95% CI = 2% to 17%); and breast cancer (11%, 95% CI = 4% to 19%). Compared with the general population, these women were at statistically significantly elevated risks of colorectal cancer (SIR = 39.9, 95% CI = 27.2 to 58.3), cancer of the kidney, renal pelvis, or ureter (SIR = 28.3, 95% CI = 11.9 to 48.6), urinary bladder cancer (SIR = 24.3, 95% CI = 8.56 to 42.9), and breast cancer (SIR = 2.51, 95% CI = 1.17 to 4.14). CONCLUSIONS: Women with Lynch syndrome who are diagnosed with endometrial cancer have increased risks of several cancers, including breast cancer.
BACKGROUND:Lynch syndrome is an autosomal dominantly inherited disorder caused by germline mutations in DNA mismatch repair (MMR) genes. Previous studies have shown that MMR gene mutation carriers are at increased risk of colorectal, endometrial, and several other cancers following an initial diagnosis of colorectal cancer. We estimated cancer risks following an endometrial cancer diagnosis for women carrying MMR gene mutations. METHODS: We obtained data from the Colon Cancer Family Registry for a cohort of 127 women who had a diagnosis of endometrial cancer and who carried a mutation in one of four MMR genes (30 carried a mutation in MLH1, 72 in MSH2, 22 in MSH6, and 3 in PMS2). We used the Kaplan-Meier method to estimate 10- and 20-year cumulative risks for each cancer. We estimated the age-, country-, and calendar period-specific standardized incidence ratios (SIRs) for each cancer, compared with the general population. RESULTS: Following endometrial cancer, women carrying MMR gene mutations had the following 20-year risks of other cancer cancers: colorectal cancer (48%, 95% confidence interval [CI] = 35% to 62%); cancer of the kidney, renal pelvis, or ureter (11%, 95% CI = 3% to 20%); urinary bladder cancer (9%, 95% CI = 2% to 17%); and breast cancer (11%, 95% CI = 4% to 19%). Compared with the general population, these women were at statistically significantly elevated risks of colorectal cancer (SIR = 39.9, 95% CI = 27.2 to 58.3), cancer of the kidney, renal pelvis, or ureter (SIR = 28.3, 95% CI = 11.9 to 48.6), urinary bladder cancer (SIR = 24.3, 95% CI = 8.56 to 42.9), and breast cancer (SIR = 2.51, 95% CI = 1.17 to 4.14). CONCLUSIONS:Women with Lynch syndrome who are diagnosed with endometrial cancer have increased risks of several cancers, including breast cancer.
Authors: Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell Journal: CA Cancer J Clin Date: 2007 Mar-Apr Impact factor: 508.702
Authors: Aung Ko Win; Noralane M Lindor; Joanne P Young; Finlay A Macrae; Graeme P Young; Elizabeth Williamson; Susan Parry; Jack Goldblatt; Lara Lipton; Ingrid Winship; Barbara Leggett; Katherine M Tucker; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Julie Arnold; A Joan Levine; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; John L Hopper; Mark A Jenkins Journal: J Natl Cancer Inst Date: 2012-08-28 Impact factor: 13.506
Authors: Paul J Goodfellow; Barbara M Buttin; Thomas J Herzog; Janet S Rader; Randall K Gibb; Elizabeth Swisher; Katherine Look; Ken C Walls; Ming-Yu Fan; David G Mutch Journal: Proc Natl Acad Sci U S A Date: 2003-05-05 Impact factor: 11.205
Authors: James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins Journal: Hum Mutat Date: 2013-03 Impact factor: 4.878
Authors: Rajani Bharati; Mark A Jenkins; Noralane M Lindor; Loïc Le Marchand; Steven Gallinger; Robert W Haile; Polly A Newcomb; John L Hopper; Aung Ko Win Journal: Gynecol Oncol Date: 2014-03-11 Impact factor: 5.482
Authors: Aung Ko Win; Daniel D Buchanan; Christophe Rosty; Robert J MacInnis; James G Dowty; Gillian S Dite; Graham G Giles; Melissa C Southey; Joanne P Young; Mark Clendenning; Michael D Walsh; Rhiannon J Walters; Alex Boussioutas; Thomas C Smyrk; Stephen N Thibodeau; John A Baron; John D Potter; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Steven Gallinger; Noralane M Lindor; John L Hopper; Dennis J Ahnen; Mark A Jenkins Journal: Gut Date: 2014-03-10 Impact factor: 23.059
Authors: Christophe Rosty; Michael D Walsh; Noralane M Lindor; Stephen N Thibodeau; Erin Mundt; Steven Gallinger; Melyssa Aronson; Aaron Pollett; John A Baron; Sally Pearson; Mark Clendenning; Rhiannon J Walters; Belinda N Nagler; William J Crawford; Joanne P Young; Ingrid Winship; Aung Ko Win; John L Hopper; Mark A Jenkins; Daniel D Buchanan Journal: Fam Cancer Date: 2014-12 Impact factor: 2.375
Authors: Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Daniel J Park; Kayoko Tao; Florence Le Calvez-Kelm; Tu Nguyen-Dumont; Nivonirina Robinot; Fleur Hammet; Fabrice Odefrey; Helen Tsimiklis; Zhi L Teo; Louise B Thingholm; Erin L Young; Catherine Voegele; Andrew Lonie; Bernard J Pope; Terrell C Roane; Russell Bell; Hao Hu; Chad D Huff; Jonathan Ellis; Jun Li; Igor V Makunin; Esther M John; Irene L Andrulis; Mary B Terry; Mary Daly; Saundra S Buys; Carrie Snyder; Henry T Lynch; Peter Devilee; Graham G Giles; John L Hopper; Bing-Jian Feng; Fabienne Lesueur; Sean V Tavtigian; Melissa C Southey; David E Goldgar Journal: Cancer Discov Date: 2014-05-02 Impact factor: 39.397